Drug Discovery- Overview
- Advinus discovers novel molecule for treatment of diabetes, ...
- Advinus sees diabetes molecule breakthrough in six months...
- Advinus Therapeutics Achieves Milestone in Drug Discovery an...
Drug Discovery
The Drug Discovery program at Advinus is presently focused on generating novel small molecule therapies for indications in three therapeutic area clusters: Metabolic Diseases, Inflammatory Diseases, and Neglected Diseases of the developing world.
Project oriented multidisciplinary teams consisting of medicinal chemists, molecular and cell biologists, biochemists, pharmacologists, physiologists and pharmaceutical scientists direct programs from hit to lead clinical candidates. Preclinical and early clinical development is also carried out by the Advinus team. Our collaborative drug discovery activity generates intellectual property that will be available for licensing at any stage from clinical candidacy onward.
Project oriented multidisciplinary teams consisting of medicinal chemists, molecular and cell biologists, biochemists, pharmacologists, physiologists and pharmaceutical scientists direct programs from hit to lead clinical candidates. Preclinical and early clinical development is also carried out by the Advinus team. Our collaborative drug discovery activity generates intellectual property that will be available for licensing at any stage from clinical candidacy onward.
Metabolic Diseases
The primary focus in Metabolic Diseases is in
In the inflammatory diseases area, our main thrust is in respiratory diseases such as asthma and chronic obstructive pulmonary disease(COPD) and in autoimmune disorders such as rheumatoid arthritis. Osteoarthritis and psoriasis, which have many common underlying molecular mechanisms, will also be added to the effort as adjunct to existing programs in the above indications. The concept of multifunctional non-steroidal anti-inflammatory agents will be fully exploited to provide therapies for specific indications, after testing in appropriate models and early clinical trials for optimal activity.
Diseases such as Leishmaniasis, dengue fever, tuberculosis, leprosy and malaria continue to ravage the populations of the developing world. The high cost of discovering new therapies has discouraged global pharmaceutical companies from investing into this area. Advinus is dedicating efforts to develop novel therapies for neglected diseases.
